Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elite Pharma signs agreement with Hi-Tech Pharmacal
Under the agreement Hi-Tech Pharmacal will be responsible for submitting the abbreviated new drug application (ANDA) for the finished product, which will be filed under Hi-Tech Pharmacal’s name.
Under the agreement Hi-Tech Pharmacal will be responsible for submitting the abbreviated new drug application (ANDA) for the finished product, which will be filed under Hi-Tech Pharmacal’s name.
The company has received the US Food and Drug Administration (FDA) clearence for Prontosan Wound Management Gel for OTC use in November 2010. B Braun Medical said the
Under the agreement, both the parties will are expected to study pioglitazone, an active ingredient of Takeda‘s Actos (pioglitazone HCl) in connection with TOMM40 biomarker and alzheimer’s disease.
The range of alternatives that will be assessed could include minority investment or strategic alliance, a merger or sale of some or all of Prosidion’s assets. Oxford-based Prosidion
The data analysis used the recently introduced SeqSolve Next Generation Sequencing (NGS) functional bioinformatics analysis software and Direct RNA Sequencing. The SeqSolve analysis software is an independent, multi-organism
With this tie up Greenway Medical is expected to integrate DiagnosisONE’s CDS solutions into its EHR solution to deliver real-time, patient-specific alerts at the point of care. Greenway
The proof of concept study will evaluate the potential to achieve sustained viral response 24 weeks post treatment with an oral, once-daily treatment regimen in patients across HCV
The study compares elvitegravir to Merck & Co’s drug Isentress, and will now last 96 weeks instead of 48 weeks, reported Bloomberg.com. Gilead said the extension will allow
The milestone was triggered by the initiation of a Phase 2 clinical study evaluating BAY 86-9766 in combination with sorafenib (Nexavar; Bayer, Onyx Pharmaceuticals) for the treatment of
As per the agreement, GSK will pay research funding as well as a sum of $20m as an upfront payment to Epizyme. Additionally, GSK is also responsible to